Search

everythinglearnresearchcommunity

for

Search:↓

JAK inhibitors are more effective and safer for treating alopecia areata than dupilumab and apremilast.

Etanercept effectively treated a severe skin condition when other treatments failed.

Guselkumab significantly improves psoriasis symptoms within 12 weeks.

Guselkumab effectively reduces fatigue in Psoriatic Arthritis patients over two years.

Anti-CD19 therapy may help treat SLE and NMOSD.

Adalimumab helped control a child's severe eye disease when other treatments failed.

Stopping infliximab and using strong topical steroids can regrow hair lost due to psoriasiform alopecia.

Ustekinumab treatment may reveal a genetic tendency for steatocystoma multiplex in psoriasis patients.

An elderly man's hair grew back after treatment with secukinumab, possibly due to reduced scalp inflammation or the medication's direct effects.

Tofacitinib helped improve symptoms and hair growth in a patient with Aicardi-Goutières syndrome.

JAK inhibitors show promise for treating skin conditions like eczema, hair loss, and psoriasis.

JAK inhibitors show promise for treating various skin disorders effectively and safely.

ICI therapy increases the risk of gastrointestinal and endocrine issues in psoriasis patients.

Omalizumab can cause temporary hair loss but still works well for chronic urticaria.

A woman with severe angioedema improved significantly after treatment with rituximab.

ZD1839 (Iressa) causes skin and hair side effects, treatable with tretinoin cream and minocycline.

JAK-inhibitors are effective for treating psoriasis and show promise for other skin diseases.

Upadacitinib improved multiple immune-related conditions in one patient.

Ocrelizumab may cause delayed hair loss in some patients.

JAK inhibitors show promise for treating skin disorders like alopecia, eczema, and psoriasis.

Upadacitinib and narrowband UVB effectively treated a child's vitiligo and alopecia areata.

Mogamulizumab, a skin cancer drug, may cause hair loss similar to alopecia areata.

Immune checkpoint inhibitors can increase the risk of autoimmune skin diseases, especially bullous pemphigoid.

Tofacitinib is a promising treatment for children with rheumatic diseases.

JAK inhibitors show promise in treating difficult skin diseases.

Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.

Ustekinumab treatment didn't prevent frontal fibrosing alopecia.

Upadacitinib significantly improved a man's severe scalp condition when other treatments failed.